Urinary Angiostatin: a Novel Biomarker of Kidney Disease Associated with Disease Severity and Progression

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2019 Apr 5

PMID 30943905

Citations 1

Authors

Yuan-Yuan Xia

Ru Bu

Guang-Yan Cai

Xue-Guang Zhang

Shu-Wei Duan

Jie Wu

Di Wu

Xiang-Mei Chen

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to evaluate the value of urinary angiostatin levels for assessing disease severity and progression of IgA nephropathy (IgAN).

Methods: Urinary angiostatin was identified as one of the distinct proteins in samples of patients with IgAN analyzed by Raybiotech protein array, and further confirmed by enzyme-linked immunosorbent assay (ELISA).

Results: Urinary angiostatin levels were significantly higher in IgAN patients than that in healthy controls (HC) subjects and lower than in disease controls (DC) patients. The concentrations of angiostatin in urine normalized to urinary creatinine (angiostatin/Cr) were positively associated with proteinuria level. With advancing chronic kidney disease (CKD) stage, urinary angiostatin/Cr levels were gradually increased. Urinary angiostatin/Cr levels in patients with Lee's grade IV-V were significantly higher than those in Lee's grade I-II and III. We further compared urinary angiostatin/Cr levels by using Oxford classification and found the expression in patients with mesangial proliferative score 1(M1) was significantly higher than that in M0 (P < 0.001). In addition, the levels of urinary angiostatin/Cr in patients with tubular atrophy/interstitial fibrosis score 1(T1) and T2 were significantly higher than those in T0 (P < 0.01, P < 0.001, respectively). After follow-up, renal survival was significantly worse in patients with higher levels of urinary angiostatin (P < 0.05).

Conclusions: Urinary angiostatin may be a useful novel noninvasive biomarker to evaluate disease severity and progression of IgAN.

Citing Articles

Blood and urine biomarkers of disease progression in IgA nephropathy.

Duan Z, Zhang C, Chen X, Cai G Biomark Res. 2024; 12(1):72.

PMID: 39075557 PMC: 11287988. DOI: 10.1186/s40364-024-00619-4.

References

Barbour S, Reich H . Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012; 59(6):865-73. DOI: 10.1053/j.ajkd.2012.02.326. View

Zhang S, Wang J, Lu K, Mott R, Longeras R, Ma J . Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol. 2006; 17(2):475-86. DOI: 10.1681/ASN.2005020217. View

Tanaka T, Nangaku M . Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol. 2013; 9(4):211-22. DOI: 10.1038/nrneph.2013.35. View

Wu T, Du Y, Han J, Singh S, Xie C, Guo Y . Urinary angiostatin--a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics. 2013; 12(5):1170-9. PMC: 3650329. DOI: 10.1074/mcp.M112.021667. View

Rocchetti M, Papale M, dApollo A, Suriano I, Di Palma A, Vocino G . Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy. Clin J Am Soc Nephrol. 2013; 8(7):1115-25. PMC: 3700689. DOI: 10.2215/CJN.05950612. View

von Eggeling F, Davies H, Lomas L, Fiedler W, Junker K, Claussen U . Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. Biotechniques. 2000; 29(5):1066-70. DOI: 10.2144/00295rr02. View

Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi J . Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem. 2000; 275(49):38912-20. DOI: 10.1074/jbc.M005402200. View

Basile D, Fredrich K, Weihrauch D, Hattan N, Chilian W . Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol. 2004; 286(5):F893-902. DOI: 10.1152/ajprenal.00328.2003. View

Cattran D, Coppo R, Cook H, Feehally J, Roberts I, Troyanov S . The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5):534-45. DOI: 10.1038/ki.2009.243. View

10.

Zhao Y, Zhu L, Zhou T, Zhang Q, Shi S, Liu L . Urinary CXCL1: a novel predictor of IgA nephropathy progression. PLoS One. 2015; 10(3):e0119033. PMC: 4376727. DOI: 10.1371/journal.pone.0119033. View

11.

Aulakh G, Balachandran Y, Liu L, Singh B . Angiostatin inhibits activation and migration of neutrophils. Cell Tissue Res. 2013; 355(2):375-96. DOI: 10.1007/s00441-013-1753-0. View

12.

Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K . The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012; 82(7):790-6. PMC: 3443545. DOI: 10.1038/ki.2012.197. View

13.

Satoh M, Kidokoro K, Ozeki M, Nagasu H, Nishi Y, Ihoriya C . Angiostatin production increases in response to decreased nitric oxide in aging rat kidney. Lab Invest. 2013; 93(3):334-43. DOI: 10.1038/labinvest.2012.171. View

14.

Li L, Liu Z . Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004; 66(3):920-3. DOI: 10.1111/j.1523-1755.2004.00837.x. View

15.

DAmico G . Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000; 36(2):227-37. DOI: 10.1053/ajkd.2000.8966. View

16.

Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran D . Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62(5):891-9. DOI: 10.1053/j.ajkd.2013.04.021. View

17.

Donadio J, Grande J . IgA nephropathy. N Engl J Med. 2002; 347(10):738-48. DOI: 10.1056/NEJMra020109. View

18.

OReilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M . Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79(2):315-28. DOI: 10.1016/0092-8674(94)90200-3. View